Remedy Health buys HealthCentral, promises broader ad reach

Share this article:

Health information site HealthCentral has been acquired by Remedy Health, a multimedia provider of content and tools designed to help people manage disease, the firms said today.

Terms of the deal, expected to close this week, were not disclosed by the companies, both of which are owned by private investors.

HealthCentral's network of bloggers and expert patients in a variety of topic areas supplements the digital side of the Remedy media portfolio, which spans mobile, print and point-of-care information and technology products.

“With the acquisition of HealthCentral, we've dramatically increased our online reach, sales capacity and our ability to create industry leading health information and technology applications,” stated Mike Cunnion, CEO of Remedy. “The combination creates exciting opportunities to provide even more value to our audiences, customers and strategic partners.”

The new company said its reach now includes 23 million unique monthly visitors to its health websites—the combined total of the two firms' online health properties.

In October, HealthCentral drew only 3.2 million unique visitors, according to data from comScore. Remedy's online traffic figures were not immediately available.

Remedy already reaches more than 17 million patients and caregivers at pharmacy counters nationwide through magazines and newsletters, has a 20-million member customer database, and keeps a network of more than 600,000 physicians, it said.

HealthCentral CEO Chris Schroeder will remain involved in the business as a consultant to Remedy and the board of directors, and has been named an advisor to Polaris Ventures, one of a number of HealthCentral investors. Remedy is owned by private investment firm Veronis Suhler Stevenson (VSS).

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...